Tactile Systems Technology, Inc. Announces Executive Changes
January 06, 2021 at 02:41 am IST
Share
On December 31, 2020, Dr. Cheryl Pegus notified Tactile Systems Technology, Inc. (the Company") that she was resigning from her position as a member of the board of directors, effective on December 31, 2020. On December 31, 2020, the Company's board of directors elected Sheri Louise Dodd and Deepti Jain to serve as members of the board and fixed the size of the board at eight directors, all effective as of January 1, 2021. Ms. Dodd was also appointed to serve as a member of the Compensation and Organization Committee and the Nominating and Corporate Governance Committee of the board. Ms. Dodd is 55 years old and currently serves as Vice President and General Manager at Medtronic plc. At Medtronic, Ms. Dodd oversees Care and Management Services. She joined Medtronic in March 2010 and has served in vice president positions including healthcare economics and market access; clinical research, health economics and policy; non-intensive diabetes therapies, and telehealth. Ms. Dodd held various positions with Johnson & Johnson, most recently as Vice President of Health Economics and Reimbursement. Ms. Jain was also appointed to serve as a member of the Audit Committee and Compliance and Reimbursement Committee of the board. Ms. Jain is 52 years old and served as the President of Anthem's pharmacy benefit management division, IngenioRx through November 2020, and was responsible for all functions including sales and account management, clinical programs, operations, client analytics, financial performance, underwriting, internal audit coordination, compliance, and market strategy. Ms. Jain held various positions with Medco Health Solutions Inc., between 1998 and 2012, most recently as Chief Financial Officer and Senior Vice President of Finance for the health plan division.
Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company providing therapies for people with chronic disorders. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. The Company markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. The Company's Entre system is a basic pneumatic compression device. Kylee, its free mobile application, helps patients learn about lymphedema.